Application of diacerein to prepare medicine for treating diabetic nephropathy

A technology of diabetic nephropathy and diacerein, which is applied in drug combinations, urinary system diseases, metabolic diseases, etc., can solve the problems of unreported use of diacerein, and achieve the treatment of non-specific vascular injury and interstitial injury, Improve the effect of renal pathological changes and insulin resistance

Inactive Publication Date: 2013-05-22
KIDNEY DISEASES INST P L A
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0025] However, the prior art does not report the use of diacerein in the medicine for the treatment of diabetic nephropathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of diacerein to prepare medicine for treating diabetic nephropathy
  • Application of diacerein to prepare medicine for treating diabetic nephropathy
  • Application of diacerein to prepare medicine for treating diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0058] Experimental example 1. Therapeutic effect of diacerein on alloxan-induced type I diabetes in mice.

[0059] Experimental method: Alloxan 80 mg / kg was injected into the tail vein of Kunming mice weighing 20±1 g, once a week, for a total of 2 injections. One week after the last injection, blood was collected from the tail to measure fasting blood glucose, and mice with fasting blood glucose greater than 13 mmol / L were regarded as type I diabetic mice.

[0060]The selected mice were randomly grouped according to the level of blood sugar: model control group: intravenous injection or intragastric administration of the same volume of solvent; treatment group: intragastric administration, diacerein 100mg / kg, 10 mice in each group, half male and half male , administer once a day, measure the food intake and water intake of the mice every day, draw the change curve of the weekly food intake and water intake of the mice, and continue for 10 weeks. At the end of the 6th week an...

experiment example 2

[0063] Experimental example 2, the therapeutic effect of diacerein on type 2 diabetes mellitus induced by streptozotocin

[0064] Experimental method: Streptozotocin 100 mg / kg was injected into the tail vein of C57BL / 6 mice weighing 20±1 g, and nicotinamide 100 mg / kg was injected intraperitoneally, once a week, for a total of 3 injections. One week after the last injection, blood was collected from the tail to measure fasting blood glucose, and mice with fasting blood glucose of 9-12 mmol / L were regarded as type II diabetic mice.

[0065] The selected mice were randomly grouped according to the level of blood sugar: model control group: intravenous injection or intragastric administration of the same volume of solvent; treatment group: intragastric administration, diacerein 100mg / kg, 10 mice in each group, half male and half male , administered once a day for 8 consecutive weeks. At the end of the 5th week and the 8th week of treatment, the fasting blood glucose was measured ...

experiment example 3

[0068] Experimental Example 3, Preventive Effect of Diacerein Alloxan-Induced Type I Diabetes in Mice

[0069] The establishment of the diabetes model was the same as in Experiment 1, and the drug was administered from 7 days before the establishment of the model. The dose was the same as in Experiment 1, and the drug was administered once a day.

[0070] Results: Diacerein can prevent alloxan-induced increase in blood glucose in mice with type I diabetes (see Figure 9 ).

[0071] The above results indicated that diacerein had a preventive effect on alloxan-induced type I diabetes in mice.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of diacerein to prepare medicines for preventing and treating diabetic nephropathy. Diacerein is taken as a raw material of an active pharmaceutical ingredient and combined with a pharmaceutically-acceptable adjuvant to prepare a pharmaceutical composition for preventing and treating diabetic nephropathy, wherein the composition contains an effective treatment dose of the diacerein and a pharmaceutically-acceptable carrier. A research on studying the diacerein capability of protecting a diabetic rat kidney through adopting streptozotocin to induce an experimental diabetic rat model accidentally discovers that the diacerein can reduce the glycated hemoglobin level and urinary albumin excretion rate of the blood of the diabetic rat, inhibits renal cortex protein non-enzyme advanced glycation end products from forming and improves renal pathology and lesion.

Description

technical field [0001] The present invention relates to a medicinal compound, in particular to a 4,5-bis(acetoxy)-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acid (diacerein) in the preparation Use in medicines for preventing and treating diabetic nephropathy. Background technique [0002] The incidence of diabetes will increase globally in the next 10 years. Among them, life-threatening diabetic nephropathy is the leading cause of diabetes death in Western countries, and it is also becoming the main cause of diabetes death in Asia and developing countries in the future. At present, measures to reduce the risk of diabetic nephropathy mainly include strict control of blood sugar, high blood pressure and restriction of dietary protein intake, which can reduce the risk of death caused by renal failure by 20%. [0003] Diabetic nephropathy manifests as changes in glomerular function and structure, including increased glomerular filtration, thickened glomerular basement membr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/222A61P13/12A61P3/10
Inventor 刘志红王广基章海涛
Owner KIDNEY DISEASES INST P L A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap